|
|
|
|
Office Locations:
|
1440 O’Brien Dr Suite D
PO Box 7237
Menlo Park, CA 94025
Phone: 650-461-4503
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Lagunita Biosciences is a healthcare investment company and incubator that creates and grows early stage companies to commercialize impactful translational science that addresses significant clinical needs. The firm evaluates opportunities in five key areas that correspond to the strengths and expertise of its team and network: Ophthalmology, Protein engineering and drug discovery, Surgical devices, Optical diagnostics and therapeutics, and Mobile health.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Christine Banian | |
| |
Director | |
| Daniel V. Palanker | |
PhD | |
Venture Partner | |
| Darius Kharabi | |
JD, MBA | |
Co-Founder | |
| David Myung | |
MD, Phd | |
Venture Partner | |
| Mark S. Blumenkranz | |
MD, MMS | |
Chairman, Founding Director | |
|
|
|
|
|
|
|
